Contraception (Birth Control) and Family Planning PubHealthInfo

[PubHealth.info Homepage] [Category Homepage] [Disclaimer/Copyrights] [Feedback]

Thank you for your kind visit to PubHealth.info®, an information portal created in technical collaboration with PakMed Biomedical Solutions * * * PubHealth.info® presents hundreds of thousands of informative Web pages on a variety of public health issues / issues * * * An ultimate source of information for teachers, students and research workers who need to find information on various public health issues, like population planning, contraception, HIV AIDS, STDs, maternal and child health, communicable and non-communicable disease, etc. * * * PubHealth.info® regularly updates the repository of these hundreds of thousands of informative Web pages * * * PubHealth.info® is one of the world's largest repositories and information portals with online Web pages on public health issues particularly those pertaining to developing countries!

PubHealth.info® (a subsidiary of PakMed) presents scientific information mainly based on abstracts of articles published on a variety of public health issues/topics, particularly encompassing population planning, disease prevention, maternal and child health, and communicable and non-communicable diseases (like HIV AIDS, malaria, etc) that are affecting a significant portion of population in developing and developed countries. Here you can find abstracts of articles published on a variety of public health topics under category "Contraception (Birth Control) and Family Planning". Contraception (birth control) is a regimen of one or more actions, devices, or medications followed in order to deliberately prevent or reduce the likelihood of a woman becoming pregnant or giving birth. Therefore contraception is the utilization of various and sundry surgical procedures, devices, practices, agents, or drugs with the intention of preventing conception or impregnation (pregnancy). Methods and intentions typically termed birth control may be considered a pivotal ingredient to family planning. Birth control is a controversial political and ethical issue in many cultures and religions, and although it is generally less controversial than abortion specifically.

YEAR: 1995

CATEGORY: Contraception (Birth Control) and Family Planning

TITLE

Prospective study of contraception with levonorgestrel.

AUTHORS

Chernev T; Ivanov S; Dikov I; Stamenkova R

SOURCE

PLANNED PARENTHOOD IN EUROPE. 1995 Aug;24(2):25.

ABSTRACT

A 6-month prospective study of 120 clients of the Bulgarian Family Planning Association was undertaken to

document the use, effectiveness, and side effects of the postcoital contraceptive Postinor. 40 of the women used

Postinor during 6 cycles, 31 during 5 cycles, 29 during 4 cycles, and 20 during 3 or fewer cycles (total of 570 cycles).

Most took 1 tablet within an hour of each intercourse (they were instructed not to use the method more than 4 times

per month), but some took 2-4 tablets simultaneously. This misuse resulted in badly tolerated side effects. Side

effects occurred in 50% of the clients and included bleeding, delayed menstruation, nausea, headaches, breast

tenderness, severe menstrual bleeding, irritability, and weight gain. Four of the subjects became pregnant (these

women took the pill a day or more after intercourse). The side effects occurred more frequently in the women who

took the most tablets during a month. It was concluded that Postinor should be reserved for emergency use and that

clients must be properly counseled about its use and side effects. (PubHealth.info Document ID: CONT2T 3030-06)

PubHealth.info NOTE: The author(s) of this article titled, "Prospective study of contraception with levonorgestrel.",

is(are) Chernev T; Ivanov S; Dikov I; Stamenkova R. The source of this article is "PLANNED PARENTHOOD IN

EUROPE. 1995 Aug;24(2):25.". This article was published in 1995 in English language(s). (PubHealth.info®

Document ID: CONT2T 3030-06. All rights reserved with PubHealth.info) PIN: 8030

This page is optimized to be viewed by Java script enabled Microsoft® Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels.